跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 70,008 条关于
“vesicular monoamine transmitter 2”
全部
70,008
临床试验
47,272
药物
7,355
机构
1,418
资讯
13,963
5个月前
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Adding First-in-Class PWS Treatment
去年
AI-Discovered Drug SOM3355 Shows Promise in Treating Huntington's Disease
去年
Neurocrine Launches Phase 1 Trial of Novel VMAT2 Inhibitor for Neurological Disorders
5年前
Luye Pharma's Next-Generation VMAT2 Inhibitor LY03015 to Begin Clinical Trials in the U.S.
去年
Phase 4 KINECT-PRO Trial Shows Ingrezza Significantly Improves Quality of Life in Tardive Dyskinesia Patients
9个月前
Neurocrine's Phase 3 Valbenazine Trial for Dyskinetic Cerebral Palsy Fails to Meet Primary Endpoints
10个月前
Neurocrine Review Reveals Key Differences Between FDA-Approved Tardive Dyskinesia Treatments
去年
Serina Therapeutics Advances Once-Weekly Injectable VMAT2 Inhibitor for Tardive Dyskinesia Treatment
8个月前
INGREZZA Demonstrates Nearly Two-Fold Higher VMAT2 Target Occupancy Than AUSTEDO XR in Head-to-Head Study
12个月前
Real-World Data Show AUSTEDO XR Delivers High Patient Satisfaction and Movement Improvement in Tardive Dyskinesia
第 1 页，共 1397 页
上一页
下一页
